Skip to main content Help with accessibility Skip to main navigation

DAPAGLIFLOZIN tablets (Forxiga®) for symptomatic chronic heart failure with reduced ejection fraction

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 25 - Nov - 2021
Body System:
Amber recommended
DAPAGLIFLOZIN tablets (Forxiga®) for symptomatic chronic heart failure with reduced ejection fraction

The Pan Mersey Area Prescribing Committee recommends the prescribing of DAPAGLIFLOZIN tablets (Forxiga®) for symptomatic chronic heart failure with reduced ejection fraction, following specialist recommendation in accordance with NICE TA679.